Skip to content
Doctor licensed in Poland · PWZ 3211301 Prescription on the EU model Every day, 5am to 11pm (Irish time)

Wegovy (semaglutide): how it works, doses and safety

Wegovy contains semaglutide and is licensed for weight management, alongside a reduced-calorie diet and more physical activity. It comes as a pen injected once a week and, for adults, as a tablet taken once a day. This page explains how it works, how each form is dosed, how it differs from Ozempic, which contains the same substance, which side effects are reported most often and who needs to be careful.

What Wegovy is used for

According to section 4.1 of the summary of product characteristics (SmPC), Wegovy is used for weight management, including weight loss and weight maintenance, in adults with obesity or with overweight and at least one weight-related condition. The examples given are prediabetes or type 2 diabetes, high blood pressure, abnormal blood fats (dyslipidaemia), obstructive sleep apnoea and cardiovascular disease. It is always used together with a reduced-calorie diet and increased physical activity.

The injection is also licensed for adolescents aged 12 and over with obesity and a body weight above 60 kg, with its own rules for review. The tablet is licensed for adults only. An overview of all the weight management injections is on our page on weight loss injections.

How semaglutide works

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1, the hormone it imitates. It binds to and activates the GLP-1 receptor, which is present in several areas of the brain involved in regulating appetite. The SmPC reports that semaglutide reduces energy intake, increases feelings of satiety, fullness and control of eating, and reduces hunger and the frequency and intensity of cravings.

Semaglutide also delays the emptying of the stomach. That helps explain the stomach side effects and is the reason the SmPC asks for care with some medicines taken by mouth at the same time.

Pens, tablets and strengths in Ireland

In the HPRA list of authorised medicines, Wegovy has 15 licences: pre-filled pens of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and 7.2 mg, and tablets of 1.5 mg, 4 mg, 9 mg and 25 mg.

The SmPC describes single-dose pens, sold in packs of four, and multi-dose FlexTouch pens, and it notes that not all pack sizes may be marketed. The pens are kept in a fridge (2 °C to 8 °C), away from the cooling element, and must not be frozen. A single-dose pen may be kept out of the fridge for up to 28 days at no more than 30 °C and is then discarded; a FlexTouch pen can be used for 6 weeks after first use. The tablets come in blister packs of 10, 30 or 90.

Dose of the weekly injection

Treatment starts at 0.25 mg once a week. To reduce the likelihood of stomach side effects, the dose is increased every four weeks over a 16-week period to the maintenance dose of 2.4 mg once a week. If stomach symptoms are significant, the next increase can be delayed or the previous dose used until they improve.

If needed, adults who had obesity when treatment started can move to 7.2 mg once a week after at least four weeks on 2.4 mg. If 7.2 mg brings no further improvement in body weight, the dose goes back to 2.4 mg. The 7.2 mg dose is given either as one injection of 7.2 mg or as three injections of 2.4 mg, depending on the pen, placed at least 5 cm apart. For adolescents, doses above 2.4 mg are not recommended.

WeeksWeekly dose (SmPC 4.2, Table 2)
1-40.25 mg
5-80.5 mg
9-121 mg
13-161.7 mg
From week 172.4 mg maintenance dose
Optional, adults, after at least 4 weeks on 2.4 mg7.2 mg maintenance dose

The Wegovy tablet

The tablet is taken once a day. It starts at 1.5 mg for four weeks and then steps up to 4 mg, 9 mg and 25 mg, with at least four weeks at each dose; 25 mg is the maintenance dose and the maximum. You take only one tablet a day and never several tablets to reach a higher dose. The SmPC says the previous dose can be kept if needed.

How you take it matters for absorption. Take the tablet on an empty stomach, after fasting for at least 8 hours, and swallow it whole with a sip of water (up to half a glass, 120 ml); do not split, crush or chew it. Then wait at least 30 minutes before eating, drinking or taking other medicines, because a shorter wait reduces how much semaglutide is absorbed. If you miss a tablet, skip it and take the next one the following day.

The SmPC describes switching between the two forms. People on the 25 mg tablet can move to the 2.4 mg weekly injection the day after their last tablet, and people on the 2.4 mg injection can start the 25 mg tablet one week after their last injection. The SmPC adds that the effect of a switch cannot easily be predicted, because absorption of the tablet varies more.

Injecting, missed doses and changing the day

The injection goes under the skin of the abdomen, thigh or upper arm, once a week, at any time of day, with or without meals. You can change the injection site. A missed dose should be given as soon as possible within 5 days; after more than 5 days, skip it and inject the next dose on your usual day. If several doses are missed, the SmPC suggests considering a lower dose when treatment restarts. You can change your injection day as long as at least 3 days pass between two doses. Read the instructions for use in the package leaflet before you first use a pen.

Ozempic and Wegovy: the same substance, different licences

Ozempic also contains semaglutide, but it is a separate product with a different licence. Section 4.1 of the Ozempic SmPC limits it to adults with type 2 diabetes that is not controlled well enough, as an addition to diet and exercise, either on its own when metformin is not suitable or with other diabetes medicines. It has no weight management indication, so using Ozempic for weight loss alone falls outside its licence.

The dose schedules differ too. Ozempic starts at 0.25 mg once a week, moves to 0.5 mg after four weeks and can be increased to 1 mg and then 2 mg, each after at least four weeks; weekly doses above 2 mg are not recommended. Wegovy goes to 2.4 mg and, for some adults, 7.2 mg. The products are not interchangeable, and a change from one to the other is a prescribing decision. In the HPRA list, all 5 Ozempic licences are prescription only and may not be renewed (category A). A side-by-side comparison is in our article comparing Mounjaro, Wegovy and Ozempic.

Side effects of Wegovy

The side effects reported most often are gastrointestinal and mainly occur while the dose is being increased. In the 68-week trials, nausea affected 43.9% of people on semaglutide (16.1% on placebo), diarrhoea 29.7%, vomiting 24.5%, constipation 24.2% and abdominal pain 19.7%. Most episodes were mild or moderate; the median duration was 8 days for nausea, 2 days for vomiting and 3 days for diarrhoea, while constipation lasted longer. Stomach side effects led 4.3% of people to stop treatment for good.

The package leaflet also lists headache and feeling weak or tired as very common. Common side effects include dizziness, a change in taste, a change in skin sensation, gastritis, reflux, indigestion, burping, wind, bloating, gallstones, hair loss and injection site reactions. In the trials, gallstones were reported in 1.6% of people on semaglutide and gallbladder inflammation in 0.6%. Hair loss was reported more often in people who lost 20% of their weight or more, and more often with 7.2 mg.

  • Severe, long-lasting pain in your stomach, which may move to your back, can be acute pancreatitis: see a doctor immediately.
  • Difficulty breathing, swelling of the face or throat, light-headedness or a fast heartbeat can be a severe allergic reaction: get medical help immediately.
  • A sudden or gradually worsening loss of vision, which may be painless, needs to be reported to a doctor immediately.
  • A severe form of constipation with stomach ache, bloating and vomiting can be a bowel obstruction and needs urgent assessment.

Warnings and who needs care

The only contraindication in section 4.3 is hypersensitivity to semaglutide or to an ingredient. Section 4.4 lists the situations that need caution. Nausea, vomiting and diarrhoea can cause dehydration, which in rare cases has led to worse kidney function, so you should avoid losing too much fluid. If pancreatitis is suspected, semaglutide is stopped, and caution is advised if you have had pancreatitis before. Epidemiological studies show an increased risk of NAION, a condition of the optic nerve; a sudden loss of vision needs an eye examination, and semaglutide is stopped if NAION is confirmed.

In type 2 diabetes, semaglutide is not a substitute for insulin, the risk of low blood sugar rises with insulin or a sulphonylurea, and people with diabetic eye disease need close monitoring. With severe gastroparesis it is not recommended. The SmPC does not recommend Wegovy for people with type 1 diabetes, severe kidney impairment, severe heart failure or those using other weight management products, because it has not been studied in them. Before an operation under general anaesthesia or deep sedation, tell the team you use semaglutide, because food can stay in the stomach longer and cases of stomach contents being inhaled have been reported.

Wegovy and other medicines, including the pill

Semaglutide delays stomach emptying and could influence the absorption of other medicines taken by mouth, so the SmPC asks for caution with medicines that need to be absorbed quickly. When semaglutide is started in someone taking warfarin or a similar anticoagulant, frequent INR checks are recommended. With the tablet form, total exposure to thyroxine rose by 33% after a single dose of levothyroxine, and monitoring of thyroid function should be considered.

On the contraceptive pill, the SmPC says semaglutide is not expected to reduce the effectiveness of oral contraceptives: it did not change exposure to ethinylestradiol and levonorgestrel to a clinically relevant degree. Section 4.6 still recommends contraception for women who could become pregnant while using semaglutide. Contraception during weight management is covered on our page on contraception during weight loss treatment.

Pregnancy and breastfeeding

Semaglutide should not be used during pregnancy, because animal studies have shown reproductive toxicity and human data are limited. If you want to become pregnant, or become pregnant during treatment, it is stopped, and because it stays in the body for a long time, the SmPC asks for it to be stopped at least 2 months before a planned pregnancy. Wegovy should not be used while breastfeeding, for both the injection and the tablet.

Is Wegovy available without a prescription?

No. All 15 Wegovy licences in the HPRA list are prescription only and may not be renewed (category A), with supply through pharmacies only. The HPRA states that it is illegal to sell prescription medicines online in Ireland. Semaglutide offered for sale online without a prescription does not come through the regulated supply route.

A pharmacist in Ireland may dispense a prescription from another EEA country when certain conditions are met, including that the medicine is authorised for use in Ireland and is not a controlled drug. Semaglutide is not named in the schedules of the Misuse of Drugs Regulations 2017.

What does it cost?

We do not quote a price for Wegovy in Ireland, and the medicine is not part of our fee. Our fee covers the doctor's assessment; you pay for the medicine at the pharmacy, at the pharmacy's price. The fee for the assessment is shown on the button on this page. What the medicine costs depends on the form and strength on your prescription, and the strength of the injection changes as the dose is increased. We make no claim about whether a medicine dispensed on this prescription counts towards a medical card or the Drugs Payment Scheme.

Requesting a prescription

Requests for weight management medicines go through Weight Loss Treatment, both for starting treatment and for continuing treatment another prescriber began. You fill in a medical questionnaire, naming the medicine or describing your situation and answering questions about your health, your other medicines and your conditions. There is no video call and no telephone consultation. If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. The doctor may ask for records, test results or a reading such as your blood pressure, may advise you to be seen in person, and may decline.

If the doctor issues a prescription, you receive it as a PDF by email. You print the PDF and take the printout to a pharmacy. A pharmacist in Ireland decides whether to dispense a prescription written by a doctor in another EEA country and may decline. This is not an Irish ePrescription and it is not sent through Healthmail.

Package leaflet and medical review

The package leaflet in your pack is the reference for the pen or tablets you use, including storage and how to inject or take them. The European Medicines Agency publishes the full product information, because Wegovy is authorised centrally for the European Union. Use of semaglutide is supervised by a doctor; this page is general information and does not replace advice about your own treatment.

Medically reviewed by Damian Wojno, a doctor registered in Poland (licence no. 3211301, Regional Medical Chamber in Olsztyn). He is not on the register of the Irish Medical Council.

Is Wegovy the same as Ozempic?

Both contain semaglutide, but they are separate products. Wegovy is licensed for weight management, with weekly injections up to 2.4 mg, or 7.2 mg for some adults, and a daily tablet. Ozempic is licensed only for adults with type 2 diabetes, with weekly doses up to 2 mg. The products are not interchangeable, and using Ozempic for weight loss alone falls outside its licence.

What is the highest dose of Wegovy?

The usual maintenance dose of the injection is 2.4 mg once a week, reached after 16 weeks. Adults who had obesity when treatment started can move to 7.2 mg once a week after at least four weeks on 2.4 mg, if needed, and go back to 2.4 mg if 7.2 mg brings no further improvement. For the tablet, the maximum is 25 mg once a day. Adolescents should not use more than 2.4 mg a week.

Is there a Wegovy tablet?

Yes. The HPRA list includes Wegovy tablets of 1.5 mg, 4 mg, 9 mg and 25 mg. The tablet is taken once a day and is licensed for adults. It is taken on an empty stomach after at least 8 hours of fasting, with a sip of water, and you wait at least 30 minutes before eating, drinking or taking other medicines.

What are the most common side effects of Wegovy?

Nausea, diarrhoea, vomiting, constipation, stomach pain, headache and tiredness are very common, mostly while the dose is being increased. In the trials, nausea affected 43.9% of people on semaglutide against 16.1% on placebo, and most episodes were mild or moderate and short. Severe stomach pain that moves to the back needs a doctor immediately.

Do I need a prescription for Wegovy in Ireland?

Yes. All 15 Wegovy licences in the HPRA list, pens and tablets, are prescription only and may not be renewed (category A), and it is supplied through pharmacies only. A doctor has to assess whether it is suitable for you before it can be prescribed.

Can I use Wegovy while breastfeeding?

No. The SmPC says Wegovy should not be used during breastfeeding, for the injection and for the tablet. It should also not be used during pregnancy, and it is stopped at least 2 months before a planned pregnancy.